NUTRACEUTICALS PRECLINICAL STUDIES

Preclinical evaluation of nutraceuticals’ beneficial effects is a mandatory step to develop such treatments. Physiogenex offers nutraceuticals preclinical studies to evaluate your products targeting obesity, insulin resistance, type 2 diabetes and related metabolic disorders using our benchmarked Diet-Induced Obese (DIO) mouse, rat and hamster models.

Our models have been benchmarked with anti-obesity drugs (e.g. G 5HT2c-receptor agonist lorcaserin), vegetal extracts such as green coffee and green tea extracts, as well as prebiotics (fructo oligosaccharide and polydextrose) and probiotics (e.g. Probiotic B420 Saccharomyces Boulardii).

Our clients benefit from our long experience in handling and evaluating vegetal extracts or pre/probiotics on obesity, insulin resistance, type 2 diabetes, but also MASLD/MASH. Our > 15 years expertise allows us to deliver reliable results and to help our clients reduce the time to market for their newly developed nutraceuticals.

If you focus on gut microbiota, you will also benefit from our partnership with Vaiomer, a pioneer company providing a unique platform to sequence, analyse and quantify gut, oral, blood and tissue microbiota.